Financial Data and Key Metrics Changes - In 2025, Labcorp achieved over 7% top-line growth and 13% adjusted EPS growth, with margins improving by over 50 basis points [4][12] - For Q4 2025, enterprise revenue increased by 5.6% to $3.5 billion, with adjusted EPS growing 18% to $4.07 [13][9] - Free cash flow for the year was $1.2 billion, a 10% increase, while Q4 free cash flow was $490 million, down from $665 million due to working capital timing [12][14] Business Line Data and Key Metrics Changes - Diagnostics revenue for Q4 was $2.7 billion, up 5.5% year-over-year, with organic growth of 4.1% and acquisitions contributing 1.5% [15] - Biopharma Laboratory Services (BLS) revenue increased by 3.4% to $793 million, with central lab revenue growing 11.1% [16] - Adjusted operating income for diagnostics was $419 million (15.4% of revenue), while BLS adjusted operating income was $136 million (17.2% of revenue) [15][17] Market Data and Key Metrics Changes - The central laboratory business saw strong demand, particularly in oncology and neurology, with a trailing twelve-month book-to-bill ratio of 1.09 [9][17] - Esoteric testing accounted for 41.5% of total testing revenue in Q4, reflecting a growing trend in specialty testing [93] Company Strategy and Development Direction - Labcorp is focusing on deepening partnerships with health systems and local laboratories, having signed 13 deals that contributed over $1 billion in revenue [4][5] - The company is advancing its leadership in specialty testing, launching over 130 new tests in 2025, particularly in oncology, women's health, and neurology [6][7] - A new central laboratory facility is planned to support growth, with construction expected to begin later this year [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in strong underlying business performance for 2026, expecting enterprise revenue growth of 5.4% and adjusted EPS growth of approximately 9% [10][19] - The delay of PAMA until December 31, 2026, is seen as a positive development, but management continues to advocate for the passage of the RESULTS Act [10][54] - Management noted that the utilization environment remains healthy, driven by an aging population and increased testing [44] Other Important Information - The company plans to invest approximately 4% of revenue in capital expenditures in 2026, higher than previous years, to support long-term growth [56][20] - Two executives, Mark Schroeder and Sandy van der Vaart, will retire on April 1, with successors already appointed [10][11] Q&A Session Summary Question: How are you thinking about contributions from price and volume in 2026 guidance? - Management expects revenue growth of 5%-6% in diagnostics, with half of the organic growth coming from volume and half from price mix [25][26] Question: What are the contributions from Invitae this year? - The integration of Invitae has gone well, and it is expected to grow revenue at two to three times the overall market rate, but will not be broken out separately [29][30] Question: What impacted the fourth quarter organic volume? - Lower referrals from a large consumer genetic client and weather conditions affected organic volume, but adjustments indicate growth would have been over 2% [33][34] Question: Where do you see the biggest risks in 2026 guidance? - Risks include slightly higher or lower organic volumes and the timing of M&A impacting revenue [42][44] Question: How do you view the competitive landscape in the diagnostic business? - Management believes the diagnostic market is strong, with Labcorp expected to outperform overall market growth, particularly in specialty testing [46][47] Question: What is the status of PAMA and its impact? - The delay of PAMA is seen positively, and management will continue to advocate for the RESULTS Act while preparing to submit necessary data [53][54] Question: Can you discuss the early development business and market growth? - The early development business is expected to be relatively flat in 2026, with improvements anticipated as consolidation efforts progress [64][66]